Veraxa Biotech, Secarna hit in vitro milestone in antibody-oligonucleotide conjugate alliance

Veraxa Biotech entered a strategic research collaboration with Secarna to develop antibody oligonucleotide conjugates for autoimmune, chronic immune diseases.

Early in vitro work produced an AOC candidate with higher potency than the equivalent unconjugated oligonucleotide.

The partners are discussing next steps, aiming to advance targeted delivery to improve bioavailability and reduce off-target effects.